7 — 8 biomanufacturing firms raise hundreds of millions in funding. Only 6 slots left for demo day at the E-Trade Biomanufacturing Conference.

In 2026, 7, financing activity in the biomanufacturing sector continued to surge. According to incomplete statistics, this month's funding rounds coveredMedicine aesthetics, bio-based materials and green chemical engineering, food, agriculture, AI-enabled biomanufacturingAt the core of key racing tracks, from tens of millions to hundreds of millions in funding, from startups to IPOs, the capital landscape of biomanufacturing is accelerating its expansion.

Zhongke Xinyang completes C-round financing worth hundreds of millions, further strengthening its AI+BT synthetic biology platform

Shenzhen Zhongke Xinyang Biotechnology Co., Ltd.Completed a financing round of over 100 million yuan, led by an industry investor with Haiyuan Capital and Longgang Financial Holdings as co-investors. The companyCentered on the fusion innovation of AI and BT, focusing on the development of bioactive ingredients.Delivering high-value-added products for cosmetics, functional foods, and flavors & fragrances. This funding round will focus on building a synthetic biology platform to accelerate the development of multi-chassis cells and product commercialization.

Peptide Raw Material Pioneer Weiqi Technology Lists on Beijing Stock Exchange

7 27,Vicky TechFormally entered the Beijing Stock Exchange: two domestic beauty giants, Proya (via Proya Hainan Investment Co., Ltd.) and Giant Biogene, have joined forces. Vicky Technology specializes in cosmetic active peptides, bringing pharmaceutical R&D methodologies into the field.Development of cosmetic peptide ingredientsBuild a Chinese cosmetic ingredient brand with global influence.

China Resources Double Crane Proposes to Gain Control of Lier Chemical, Officially Entering the Pesticide Manufacturing Sector

CR SanheReleased a major asset purchase plan to acquire 23.50% of shares in Lier Chemical via cash payment, with a total transaction value of approximately 56.56 billion yuan. This cross-industry acquisition marks China Resources Double-Crane's formal entry into the sector.Pesticide ManufacturingBoth parties will engage in deep collaboration on synthetic biotechnology R&D and commercialization.

Source Biology raises nearly 100 million yuan in Series A funding

Shenzhen Yuantian Biotechnology Co., Ltd.Completed a nearly RMB 100 million Series A funding round, with investors including Beiyang Haitang Fund, Jinqiao Fund, and Guotai Haitong Investment. The company focuses onPET Plastic Enzymatic Recycling TechnologyBy directing enzyme protein engineering, developing novel immobilized enzymes, and intensifying biocatalytic processes, we achieved low-cost ton-scale fermentation production of over ten enzyme formulations and advanced the large-scale manufacturing of high-value biochemical products. This funding round will be used to expand enzyme production capacity, accelerate the commercialization of regenerated PET, and upgrade R&D capabilities.

Neubio completes nearly 2 billion C+ round financing to develop dietary nutrition ingredients using innovative drug R&D logic

NebioCompleted a C+ round of nearly 2 billion yuan, led by China Life Equity with participation from existing investor Mingxi Capital. This marks the company's second financing exceeding 100 million yuan within six months. Nubio Biology focuses on...Dietary Supplement Ingredient R&DCovering areas such as sports nutrition, weight management, cognitive health, and anti-aging. The company operates its own formulation and biomanufacturing facilities. This funding round will be primarily used for product R&D and new facility construction.

AI-driven breeding platform company Tian Neng Jingxiu completes tens of millions of yuan in Series A funding

Recently, the AI-powered biological breeding platform enterpriseSichuan Tianeng Jingxiu Biotechnology Co., Ltd.Announced the completion of a tens-of-million-yuan Series A financing round, led by Guanghua Wutong, Tianlai Fund, Boruidi, Sichuan Rural Revitalization Fund, and Haochen Capital. Kaicheng Capital served as the financial advisor for this transaction. The company focuses on...Technical Services for Maintainer Line Multiplication and Backcross BreedingTwo core business segments will enter a phase of explosive commercial growth over the next two years as the production area for male-sterile lines continues to expand.

AI-Driven Protein R&D Platform Tianwu Technology Closes Hundreds of Million RMB Series A++ Financing

7 13,Tianwu TechnologyAnnounced completion of a C++-round financing totaling hundreds of millions of yuan, jointly led by Shanghai State-owned Investment Pilot and SDIC Innovation, with participation from Juji Microfiber, Jinjing Capital, and continued investment from existing shareholders Qiming Venture Partners, Yonghua Investment, and Shanghai Science & Technology Innovation Fund. Tianwu Technology is an AI-driven, full-stack protein R&D platform. This round will primarily fund AI technology iterations and ongoing development of its core product "Xiaowu™," while acceleratingScaled deployment of AI-driven protein design capabilities across the circular economy, innovative drug development, broader healthcare, and medical consumables sectors.Further advance the transition of AI for Science breakthroughs from the lab to industrial application.

Hanhe Biosecures Funding from China Innovation Capital and Xingxiang Capital to Break Through with "Made in China" Solution: Replacing Petroleum with Agricultural and Forestry Waste

Hanhe BioAnnounced completion of tens of millions in strategic financing, led by Guoke Chuangtou with follow-on investment from funds under Xingxiang Capital. Hanhe Bio is a high-tech enterprise integrating biorefinery and new material R&D and production, and has establishedNon-food biomass biorefinery technology systems and the new materials industryThe funds will be allocated exclusively to the Hunan Anxiang Ecological Reed Negative-Carbon Bio-Manufacturing Project for Annual Production of 5 Million Tons of New Materials.

In 7, the bio-manufacturing industry saw policy breakthroughs, capacity deployment, and technology benchmarks. From medical aesthetics to agriculture, from food to materials, with AI empowerment and production line launches, coordinated progress across five key sectors is painting a clear industry picture: bio-manufacturing is no longer just a cutting-edge concept—it's an accelerating supply chain taking shape.